At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program and Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, presented results from the DESTINY-Breast06 study, showing that Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki), also called T-DXd, was better than chemotherapy for metastatic, hormone receptor-positive, HER2-low or -ultralow breast cancer that grew after one or more hormonal therapy medicines. Listen to the episode to hear Dr. Bardia explain:<ul>
<li>results of the study</li>
<li>what HER2-low and -ultralow breast cancer is</li>
<li>whether people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer should have additional HER2 testing</li>
</ul>

At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program and Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, presented results from the DESTINY-Breast06 study, showing that Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki), also called T-DXd, was better than chemotherapy for metastatic, hormone receptor-positive, HER2-low or -ultralow breast cancer that grew after one or more hormonal therapy medicines. Listen to the episode to hear Dr. Bardia explain: results of the study what HER2-low and -ultralow breast cancer is whether people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer should have additional HER2 testing

Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer

New episodes publish every Tuesday at 5 a.m. ET.

Covering everything from the latest breast cancer treatments to the rising costs of care to what it’s like to be diagnosed when you’re pregnant, The Breastcancer.org Podcast explores all things breast cancer. Join host and veteran science reporter Jamie DePolo as she talks to world-renowned oncologists, breast cancer advocates, and everyday people affected by breast cancer. Guests have included oncologists Hope Rugo, Dennis Slamon, and Eleonora Teplinsky, as well as advocates from METAvivor, Breast Cancer Action, SHARE, and GRASP. The Breastcancer.org Podcast is produced by Breastcancer.org, a nonprofit organization dedicated to providing the most reliable and up-to-date information about breast cancer. Learn more about breast cancer and join our community at www.breastcancer.org.

Medicine

Health & Fitness

Education

New episodes publish every Tuesday at 5 a.m. ET. Covering everything from the latest breast cancer treatments to the rising costs of care to what it’s like to be diagnosed when you’re pregnant, The Breastcancer.org Podcast explores all things breast cancer. Join host and veteran science reporter Jamie DePolo as she talks to world-renowned oncologists, breast cancer advocates, and everyday people affected by breast cancer. Guests have included oncologists Hope Rugo, Dennis Slamon, and Eleonora Teplinsky, as well as advocates from METAvivor, Breast Cancer Action, SHARE, and GRASP. The Breastcancer.org Podcast is produced by Breastcancer.org, a nonprofit organization dedicated to providing the most reliable and up-to-date information about breast cancer. Learn more about breast cancer and join our community at www.breastcancer.org.

Share Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer

Sign up to save your podcasts

Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer

Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer

More shows like Breastcancer.org Podcast

TED Radio Hour

Well Beyond 40

The mindbodygreen Podcast

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

The Proof with Simon Hill

Dhru Purohit Show

The Dr. Hyman Show

Breast Cancer Conversations

Life Kit

This Is So Awkward

Dr. Streicher’s Inside Information: Menopause, Midlife, and More

The Mel Robbins Podcast

The Dr. Gabrielle Lyon Show

Keeping Abreast with Dr. Jenn

The Menopause and Cancer Podcast